AIMPACT update, May 15 (UTC+8): Astraea is an AI-native platform focused on automating biostatistical workflows in clinical trials. By inputting raw clinical data, trial protocols, and study metadata, the platform automatically generates SDTM and ADaM datasets compliant with CDISC standards, TFLs (tables, figures, listings), and FDA-ready outputs. According to customer feedback, traditional processes typically require nine months and a team of 5–10 people, while Astraea reduces this to just a few days. The platform currently focuses on oncology and rare disease research. Co-founders Joshua Wang (CEO) and Sanmay Sarada (CTO) both hail from Stanford and bring expertise in AI systems and clinical data infrastructure. The platform has received support from Y Combinator. (Source: InFoQ)
Astraea AI Platform Reduces New Drug Approval Cycle to Days
KuCoinFlashShare
Summary
The Astraea AI Platform Reduces New Drug Approval Cycle to Days. The AI-native platform automates biostatistical processes in clinical trials, generating CDISC-compliant datasets and FDA-ready outputs. Traditional methods require nine months and a team of five to ten people, but Astraea completes the process in days. Focused on oncology and rare diseases, the platform is backed by Y Combinator. Co-founders Joshua Wang and Sanmay Sarada are Stanford alumni with expertise in AI and clinical data. This AI + crypto news update highlights new token listings in the pipeline.
Source:Show original
Disclaimer: The information on this page may have been obtained from third parties and does not necessarily reflect the views or opinions of KuCoin. This content is provided for general informational purposes only, without any representation or warranty of any kind, nor shall it be construed as financial or investment advice. KuCoin shall not be liable for any errors or omissions, or for any outcomes resulting from the use of this information.
Investments in digital assets can be risky. Please carefully evaluate the risks of a product and your risk tolerance based on your own financial circumstances. For more information, please refer to our Terms of Use and Risk Disclosure.